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Abstract: Nitrile hydratase (NHase), an industrially important enzyme that 
catalyzes the hydration of nitriles to their corresponding amides, has only 
been characterized from prokaryotic microbes. The putative NHase from the 
eukaryotic unicellular choanoflagellate organism Monosiga brevicollis 
(MbNHase) was heterologously expressed in Escherichia coli. The resulting 
enzyme expressed as a single polypeptide with fused α- and β-subunits linked 
by a seventeen-histidine region. Size-exclusion chromatography indicated 
that MbNHase exists primarily as an (αβ)2 homodimer in solution, analogous 
to the α2β2 homotetramer architecture observed for prokaryotic NHases. The 
NHase enzyme contained its full complement of Co(III) and was fully 
functional without the co-expression of an activator protein or E. coli 
GroES/EL molecular chaperones. The homology model of MbNHase was 
developed identifying Cys400, Cys403, and Cys405 as active site ligands. The 
results presented here provide the first experimental data for a mature and 
active eukaryotic NHase with fused subunits. Since this new member of the 
NHase family is expressed from a single gene without the requirement of an 
activator protein, it represents an alternative biocatalyst for industrial 
syntheses of important amide compounds. 
Abbreviations 
 NHase, nitrile hydratase;  
 ORF, open reading frame;  
 ICP-MS, inductively-coupled plasma mass spectrometry;  
 IMAC, immobilized metal affinity chromatography 
Keywords: Nitrile hydratase, Enzyme kinetics, Cobalt, Hydrolysis 
1. Introduction 
Nitrile hydratases (NHases, EC 4.2.1.84) catalyze the hydration 
of nitriles to their corresponding amides.1,2 Since the currently 
employed industrial conditions used to hydrate nitriles to amides 
(either acid or base hydration), are often incompatible with the 
sensitive structures of many industrially and synthetically relevant 
compounds, NHases have attracted substantial interest as biocatalysts 
in preparative organic chemistry. For example, acrylonitrile and 
adiponitrile are used in the production of polyacrylamide and nylon-66, 
respectively, the latter of which is one of the most important industrial 
polyamides.3 Nitriles are also often used as synthetic starting materials 
since they add an extra carbon atom to an alkyl chain. Since nitriles 
are synthesized by plants, fungi, bacteria, algae, insects and sponges, 
there are several biochemical pathways for nitrile degradation.4 
Enzymes involved in nitrile degradation pathways represent chemo-
selective biocatalysts capable of hydrating nitriles under physiological 
reaction conditions.4,5 
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X-ray crystallographic studies on bacterially-encoded NHases 
have revealed that they are α2β2 heterotetramers with an active site in 
each α subunit consisting of three cysteine residues, two backbone 
amide nitrogen's, a water molecule, and either an Fe(III) ion (Fe-type) 
or a Co(III) ion (Co-type).2 Two of the active site cysteine residues 
are post-translationally modified to cysteine-sulfinic acid (− SO2H) and 
cysteine-sulfenic acid (− SOH), respectively, yielding an unusual metal 
coordination geometry, termed a “claw-setting”. Oxidation of the 
equatorial Cys residues is critical for catalysis.6 Although the structures 
of Fe- and Co-type NHases are very similar, Fe-type NHases only bind 
Fe(III) and Co-type NHases only bind Co(III). This specificity is 
thought to be regulated by one of several open reading frames (ORFs), 
that encodes for an activator protein that has been identified just 
downstream from the structural α- and β-subunit genes in NHases.7,8,9 
Even though Co- and Fe-type NHase enzymes share high sequence 
identity, their respective activator proteins are different in size 
(~ 14 kDa for Co-type vs. ~ 47 kDa for Fe-type NHase) and share 
little or no sequence identity.10,11 The prevailing dogma is that both 
Co- and Fe-type NHase enzymes require the co-expression of an 
activator protein to be soluble and fully active.7,8,9 The exception is the 
Fe-type NHase from Comamonas testosteroni Ni1 (CtNHase), which 
was shown to be functionally expressed without the co-expression of 
an activator protein.12 
Until recently, NHases have only been found in prokaryotes; 
however, a novel gene that contains putative NHase α- and β-subunits 
was reported in several unicellular eukaryotic organisms such as 
Monosiga brevicollis, Thecamonas trahens, Sphaeroforma arctica, 
Stephanoeca diplocostata, Salpingoeca rosetta, Emiliania huxleyi and 
Aureococcus anophagefferens.13,14 Unlike prokaryotic NHases, the 
putative eukaryotic NHase ORF contains fused α- and β-subunits 
bridged by an insert that codes for multiple but variable numbers of 
His residues (Fig. 1). For example, the M. brevicollis gene encodes 
(His)17, while the gene from S. rosetta encodes only (His)2.13,14 The C-
terminus of the eukaryotic holo-protein contains the strictly conserved 
metal-binding motif (CTLCSCY) found in the α-subunit of Co-type 
NHases and the homologous cobalt-containing thiocyanate hydrolase.15 
Interestingly, no gene encoding an activator protein was identified. 
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Fig. 1. Alignment of the amino acid sequence of the eukaryotic NHase from 
M. brevicollis and prokaryotic nitrile hydratases. A) Amino acid alignment of 
the N-terminus residues of the eukaryotic NHase from M. brevicollis and 
prokaryotic NHase β-subunits. B) Amino acid alignment of the C-terminus 
residues of the eukaryotic NHase from M. brevicollis and prokaryotic NHase α-
subunits. Conserved residues among MbNHase and prokaryotic NHases are 
highlighted in black and gray. The metal-binding motif is highlighted in cyan 
and active site Co-type NHase residues are in orange. The histidine-rich 
region is highlighted in light yellow. MbNHase from M. brevicollis; Co-NHases: 
PtNHase (Pseudonocardia thermophila JCM 3095), Rh_LM, (low-molecular 
weight, Rhodococcus rhodochrous J1), Rh_HM (high-molecular weight, 
Rhodococcus rhodochrous J1); Iron-NHases: Rh_N-771 (Rhodococcus sp. N-
771), Ct (Comamonas testosteroni Ni1), Re (Rhodococcus equi TG328-2); 
SCN_alpha, SCN_beta, and SCN_gamma, cobalt thiocyanate hydrolase 
(SCNase) from Thiobacillus thioparus THI115. 
As no eukaryotic NHase enzyme has yet been described, we set 
out to determine whether the putative NHase gene from M. brevicollis 
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does indeed code for a functional NHase. The gene encoding the fused 
α- and β-subunits of the hypothetical NHase from M. brevicollis was 
heterologously expressed in E. coli. The resulting enzyme contained its 
full complement of Co(III) and was a fully functional NHase, all without 
the co-expression of an activator protein or E. coli GroES/EL molecular 
chaperones. This is the first report of a eukaryotic NHase and because 
this new member of the NHase family is expressed from a single gene 
without the requirement of an activator protein, it represents an 
alternative biocatalyst for industrial syntheses of important amide 
compounds. 
2. Materials and methods 
2.1. Materials 
Acrylonitrile, Tris-HCl, and HEPES were obtained from Sigma-
Aldrich (St. Louis, MO, USA). All other materials were purchased at the 
highest quality available. 
2.2. Plasmid construction 
Protein sequences for the α- and β-subunit genes of the putative 
MbNHase were obtained from ORF 37534 (UniProt ID A9V2C1.1) of M. 
brevicollis. The predicted gene was synthesized by Integrated DNA 
Technologies, Inc. with optimized E. coli codon usage (SI Fig. 1) and 
cloned into the pIDT-SMART kanamycin resistant vector with NdeI and 
HindIII restriction sites. The gene was subsequently digested and 
ligated into the ampicillin resistant pET21a+ (EMD Biosciences) 
expression vector to create the plasmid pSMMαβ. The sequence was 
confirmed using automated DNA sequencing at the University of 
Chicago Cancer Research Center DNA sequencing facility. 
2.3. Expression of recombinant MbNHase in the 
absence of an activator protein 
The hypothetical MbNHase gene was expressed alone, without 
co-expressing a Co-type activator protein or the E. coli chaperones 
GroES/EL, in the following manner. The pSMMαβ plasmid was freshly 
transformed into E. coli BL21(DE3) competent cells (Agilent 
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Technologies) and a single colony was used to inoculate a 50 mL LB-
Miller culture containing 50 μg/mL of carbenicillin with shaking 
overnight at 37 °C. This culture (~ 7 mL) was used to inoculate a 1 L 
culture containing 100 μg/mL of ampicillin and the cells were grown at 
37 °C until the OD600 nm reached 0.8–1.0. The culture was cooled on 
ice to 20 °C, induced with 0.1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) in the presence of 0.25 mM CoCl2 and 
expressed at 20 °C for 16 h. Cells were harvested by centrifugation at 
6370 × g for 10 min at 4 °C in a Beckman Coulter Avanti JA-10 rotor. 
Cell pellets were resuspended in buffer A (50 mM NaH2PO4 pH 8.0, 
500 mM NaCl, and 10 mM imidazole with 5% glycerol) at a ratio of 
5 mL per gram of cells, then sonicated for 4 min (30 s on 45 s off) at 
21 W using a Misonix sonicator 3000. The crude extract was obtained 
after centrifugation in a JA-20 rotor at 31,000 × g and 4 °C for 
20 min. The sample was subjected to another round of centrifugation 
before purification to remove particulate matter. 
2.4. Purification of recombinant MbNHase 
Crude extracts of MbNHase were loaded onto a 5 mL Ni(II)-
nitrilotriacetic acid (NTA) Superflow Cartridge (Qiagen) for immobilized 
metal affinity chromatography (IMAC) using an ÄKTA FPLC P-960 
column. The column was washed with four column volumes (CVs) of 
buffer A (50 mM NaH2PO4 pH 8.0, 500 mM NaCl, and 35 mM 
imidazole) followed by washes with 50 mM HEPES pH 8.0, 500 mM 
NaCl containing 60 mM and 110 mM imidazole, respectively. The 
protein was eluted with a linear gradient (0–100%) of buffer B (50 mM 
HEPES pH 8.0, 500 mM NaCl with 500 mM imidazole) over 20 CVs at a 
flow rate of 1 mL/min. Active protein fractions were pooled and 
concentrated with an Amicon Ultra-15 10,000 MWCO centrifugal filter 
unit (Millipore) resulting in ~ 10 mg/L of culture containing soluble 
MbNHase. Size-exclusion chromatography was used to remove 
remaining impurities and to assess the quaternary structure of 
MbNHase (Fig. SI-2). A 16/60 Superdex 200 prep grade (GE 
Healthcare) column was calibrated from 12.4 to 200 kDa using the 
MWGF200 gel filtration calibration kit (Sigma). Purified protein samples 
were analyzed by SDS-PAGE with a 12.5% polyacrylamide SPRINT 
NEXT GEL™ (Amresco). Gels were stained with Gel Code Blue 
(Thermo-Fisher Scientific). Protein concentration of purified protein 
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was determined using either a Coomassie (Bradford) Protein Assay Kit 
(Pierce) or by measuring the absorbance at 280 nm on a Shimadzu 
UV-2450 spectrophotometer. Theoretical molecular weights and 
protein extinction coefficients were calculated with the ExPASy 
compute pI/Mw tool.16 The molecular weight for the MbNHase 
homodimer was 111,207 g/mol with an extinction coefficient of 
143,700 cm− 1 M− 1. The molecular weight is in good agreement with 
SDS-PAGE data. 
2.5. Kinetic analysis of MbNHase 
The enzymatic activity of MbNHase towards acrylonitrile 
(acrylamide; Δε225 = 2.9 mM− 1 cm− 1) and benzonitrile (benzamide; 
Δε242 = 5.5 mM− 1 cm− 1), was measured using a Shimadzu UV-2450 
spectrophotometer. A 1 mL reaction consisted of 50 mM Tris-HCl 
buffer pH 7.0 at 25 °C and various concentrations of acrylonitrile or 
benzonitrile.17 Data analysis was performed using OriginPro 9.0 
(OriginLab, Northampton, MA). The kinetic constants Vmax and Km 
(were calculated by fitting the data to the Michaelis and Menten 
equation. One unit of enzyme activity was defined as the amount of 
enzyme that catalyzed the production of 1 μmol of the amide per 
minute at 25 °C. 
2.6. Metal analysis 
The metal content of purified protein was determined by 
inductively-coupled plasma mass spectrometry (ICP-MS). Purified 
MbNHase (1 mg) expressed in the presence and absence of added 
CoCl2. For comparison purposes, the Co-type NHase from 
Pseudonocardia thermophila JCM 3095 (PtNHase) (1 mg) was 
expressed and purified as previously described,18 and examined along 
with a control of buffer containing no protein. All protein samples were 
digested with concentrated nitric acid (0.863 mL) and heated at 70 °C 
for 1 h, allowed to cool to room temperature and then diluted to final 
concentration of 5% nitric acid. Samples were submitted for analysis 
at the Water Quality Center in the College of Engineering at Marquette 
University (Milwaukee, WI, USA). 
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2.7. Electronic absorption spectra 
Electronic absorption spectra were recorded on a Shimadzu UV-
2600 spectrophotometer equipped with a TCC-240A temperature 
controlled cell holder. Spectra of MbNHase and PtNHase were obtained 
at 25 °C in a 1 cm quartz cuvette in 50 mM HEPES buffer containing 
300 mM NaCl, pH 8.0, for MbNHase or pH 7.5 for PtNHase. 
2.8. Homology model of the MbNHase 
A homology model of the MbNHase was developed using the X-
ray crystal structure of PtNHase (PDB code:1IRE) as a template.19,20 
Sequence analysis of the target and template α- and β-subunits only, 
revealed that these proteins are of similar length, with a sequence 
identity of 29%, and exhibit no significant sequence gaps. The YASARA 
homology-building program was used to construct the structural 
homology model of MbNHase.21,22 Comparison of the energy minimized 
MbNHase α- and β-subunit homology model to the X-ray crystal 
structure of PtNHase, using the MatchMaker in UCSF Chimera, reveals 
that the MbNHase α- and β-subunit homology model displays the 
typical dimerization and catalytic domains of PtNHase with a 
Needleman-Wunsch23 score of 285 and an average RMSD of 1.129 Å 
over the aligned 354 Cα atom pairs. 
3. Results and discussion 
3.1. Sequence alignment of MbNHase with prokaryotic 
NHases 
The predicted NHase polypeptide encoded by the M. brevicollis 
ORF 37534 contains 495 amino acids.14 The first ~ 240 AA of the N-
terminus of this putative NHase align with the β-subunit of prokaryotic 
NHases (Fig. 1A), while the last ~ 240 AA of the C-terminus aligns 
with, and has high similarity (35–45%) with prokaryotic NHase α-
subunits (Fig. 1A). The α- and β-subunit regions in MbNHase are 
connected by a histidine rich region containing seventeen histidine 
residues while the C-terminus region contains the signature NHase 
metal-binding domain of Co-type NHases (Fig. 1B). 
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3.2. Characteristics of purified MbNHase 
MbNHase was expressed in E. coli without the co-expression of 
the E. coli molecular chaperones GroES/EL or an activator protein. The 
protein was purified by IMAC using the seventeen His residues 
naturally encoded in the insert between the α- and β-subunit regions 
as the tag, providing ~ 10 mg/L of soluble protein. SDS-PAGE analysis 
revealed a band with molecular weight of ~ 55 kDa (Fig. 2A), which is 
in good agreement with the theoretical molecular weight of 55.6 kDa. 
A faint second band is also observed at ~ 110 kDa, which is consistent 
with a small fraction of MbNHase homodimer (111.2 kDa) that was not 
fully denatured under the conditions used. In contrast to prokaryotic 
NHases, MbNHase is expressed as a fused protein where both the α- 
and β-subunits reside in a single polypeptide as predicted by Foerstner 
et al.14 Even though this is the first example of a fused eukaryotic 
NHase, the expression of a subunit-fused bacterial NHase from 
Pseudomonas putida24 has also been reported, however, in this case 
the subunit-fusion was accomplished by engineering a proline-glycine 
dipeptide linker between the two subunit genes by PCR. Size-exclusion 
chromatography indicated that MbNHase exists primarily as an (αβ)2 
homodimer in solution, analogous to the α2β2 homotetramer 
architecture observed for prokaryotic NHases, with a small fraction 
(< 10%) present as a monomer (Fig. SI-2). 
3.3. Kinetic characterization of MbNHase 
Kinetic analysis revealed that MbNHase expressed in the 
presence of 0.25 mM CoCl2 is capable of hydrating acrylonitrile, the 
standard substrate for NHase kinetic analysis, with a kcat of 
130 ± 3 s− 1 and a Km of 78 ± 3 mM, providing a catalytic efficiency 
kcat/Km of 1.7 s− 1 mM− 1. Since the turnover rate is in line with other 
reported Co-type NHase enzymes (kcat = 50 to 1500 s− 1),2,18 it was 
hypothesized that the metal ion was properly inserted and that both 
active site Cys residues (Cys403 and Cys405) were properly oxidized 
in the absence of an activator protein, which is typically required for 
full NHase enzymatic activity.7,8,9 MbNHase is also capable of hydrating 
benzonitrile with kcat of 33 ± 1 s− 1 and a Km = 18 ± 1 mM, providing a 
catalytic efficiency kcat/Km of 1.8 s− 1 mM− 1. These data suggest that 
MbNHase exhibits a higher affinity for aromatic nitrile substrates 
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compared to aliphatic substrates, following the trend observed for 
most Co-type NHases.4,15 
3.4. Metal analysis and spectral characterization of 
MbNHase 
A combination of UV–Vis spectroscopy and metal analysis was 
used to determine if MbNHase expressed in the absence of an activator 
protein contained its full complement of Co(III). After purification, 
MbNHase expressed in the presence of 0.25 mM CoCl2 exhibits the 
characteristic amber color of a Co-type NHase enzymes (Fig. 2B, 
inset).2 ICP-MS data indicate that MbNHase expressed in the presence 
of 0.25 mM CoCl2 contained ~ 1.8 equivalents of cobalt per 
homodimer while MbNHase expressed in the absence of CoCl2 
contained 1.6 cobalt ions per homodimer. The UV–Vis spectrum of 
MbNHase expressed in the presence and absence of cobalt shows the 
characteristic S → Fe(III) ligand-to-metal-charge-transfer (LMCT) band 
at ~ 320 nm (ε = 19,392 M− 1 cm− 1) (Fig. 2B).2 These data show that 
MbNHase contains its full complement of Co(III) and can thus be 
expressed in E. coli in the absence of a Co-type NHase activator 
protein or the E. coli molecular chaperones GroES/EL. Given the high 
iron content of LB media, these data also suggest that the MbNHase 
has high affinity for cobalt and can be classified as a Co-type NHase. 
All Fe- and Co-type NHase enzymes reported to date require the 
co-expression of an activator protein for metal ion insertion and the 
post-translational oxidation of the two equatorial active site cysteine 
residues.11,25 The only exception is CtNHase.12 For M. brevicollis, no 
ORF encoding for an NHase activator or accessory protein, which is 
usually found downstream of the prokaryotic NHase genes, has been 
reported.13,14 Based on the binding ability of MbNHase during 
purification to the Ni-NTA column material, even though no His-tag 
was engineered, it is clear that the histidine-rich region found in the 
insert between the β- and α-subunits of MbNHase is capable of tight, 
but reversible binding of divalent transition metal ions. It is tempting, 
then, to speculate that the histidine-rich insert plays a role similar to 
that of the activator protein in metal acquisition and/or insertion. 
Histidine rich regions are present in some proteins of the cobalamin 
(vitamin B12) biosynthetic pathway, e.g., the chelatase CbiX enzyme 
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from Bacillus megaterium and CobW from Pseudomonas 
denitrificans.26 Histidine rich regions are also found in 
metallochaperone and accessory proteins involved in metallocenter 
assembly of nickel hydrogenases and ureases, such as HypB from 
Bradyrhizobium japonicum and Rhizobium leguminosarum, SlyD from 
Escherichia coli and Helicobacter pylori, UreE from Klebsiella 
aerogenes, Hpn and Hpn-like proteins from Helicobacter pylori.27 
Based on the similarity of the histidine rich region with accessory 
proteins involved in the metallocenter assembly of cobalamin, 
hydrogenases, and ureases, it is possible that the histidine rich insert 
that links the β- and α-subunits of MbNHase, and those found in other 
eukaryotic NHases, play a role in cobalt binding and possible insertion 
of the cobalt ion into the active site. 
3.5. Homology model of MbNHase 
Since no three-dimensional X-ray crystal structure exists for 
MbNHase, a homology model was developed using the X-ray crystal 
structure of the prototypical prokaryotic Co-type NHase from 
Pseudonocardia thermophila JCM 3095 (PtNHase; PDB code: 1IRE) as 
a template (Fig. 3A). Only the α- and β-subunits of MbNHase were 
modeled as no suitable template structure exists for the entire 
MbNHase peptide. The α- and β-subunit model of MbNHase suggests 
that it is, in general, structurally similar to other Co-type NHase 
enzymes ( Fig. 3A). The α-subunit of MbNHase is embedded in the 
center of the β-subunit, while the N-terminus of the α-subunit forms a 
helix that is embedded among three helices from the β-subunit. The 
model reveals that within 4.0 Å of the Co(III) binding site, all of the 
amino acid residues are identical to those in PtNHase. The Co(III) ion 
of MbNHase is five coordinate and bound by C400, C403, and C405 as 
well as two backbone amide nitrogen's, where C403 and C405 are both 
modeled as oxidized cysteine-sulfinic and cysteine-sulfenic acids, 
respectively ( Fig. 3B). The oxidation of the equatorial Cys residues is 
expected since MbNHase exhibits nitrile hydratase activity and 
oxidation of the equatorial Cys residues is required for catalytic 
activity.6 Two amide nitrogen atoms and the oxidized sulfur atoms are 
roughly in the same plane as the metal ion. The sulfur atom from C400 
forms a coordination bond roughly perpendicular to this plane, which 
results in a slightly distorted square-based pyramidal geometry. On 
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the opposite side of C400, no sixth ligand such as water was modeled 
but is often observed for Co-type NHase enzymes.2 The sulfinic and 
sulfenic acid ligands are within hydrogen bonding distance of two 
strictly conserved and catalytically important β-Arg56 and β-Arg167 
residues found in Co-type NHase enzymes. These Arg residues are 
conserved in all bacterial NHases and play a role in the stabilization of 
the “claw-setting” structure through the hydrogen bonding. 
 
Fig. 3. Homology model of MbNHase. A) The MbNHase homology model for the α- and 
β-subunits only are highlighted in blue is overlaid with the X-ray crystal of PtNHase 
(PDB code:1IRE) which is in green. B) The active site of MbNHase derived from the 
homology model showing the classical “claw-setting” of an NHase. 
4. Conclusion 
The construct presented here provides the first evidence of a 
functional subunit-fused eukaryotic NHase. We found that expression 
of MbNHase does not require an NHase activator protein or the E. coli 
chaperone proteins GroEL/ES. These data are contrary to the accepted 
view regarding the strict requirement of co-expressing NHases with 
activator proteins for fully active enzymes. Based on UV–Vis and ICP-
MS data, MbNHase binds it full complement of Co(III) ions in its active 
site and the equatorial Cys residues are appropriately oxidized, which 
is a requirement for full enzymatic activity. Both metal ion insertion 
and Cys oxidation are functions previously ascribed to NHase activator 
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proteins. The homology model suggests that the MbNHase polypeptide 
encoding for the α- and β-subunits is capable of folding like a 
prototypical prokaryotic Co-type NHase. The position of the predicted 
active site residues of MbNHase align with those of PtNHase including 
the highly conserved β-Arg residues in prokaryotic Co-type NHases 
that form hydrogen bonds to the active site oxidized Cys residues.28 
Both of these β-Arg residues are catalytically important for both Fe- 
and Co-type prokaryotic NHase enzymes. Since MbNHase is a new 
member of the NHase family that is expressed from a single gene 
without the requirement of an activator protein, it represents an 
alternative biocatalyst for industrial syntheses of important amide 
compounds. 
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Appendix A. Supplementary data 
Appendix A. Supplementary data 
Supplementary information includes DNA and amino acid sequences of 
MbNHase (Fig. SI-1), a size-exclusion chromatography elution profile 
(Fig. SI-2), and an image of an SDS-PAGE for apo MbNHase (Fig. SI-
3). Supplementary data associated with this article can be found in the 
online version, at doi: 
http://dx.doi.org/10.1016/j.bbapap.2016.09.013. 
Supplementary Material 
 
Figure SI-1.  The DNA sequence encoding the nitrile hydratase from Monosiga 
brevicollis was codon-optimized for over-expression in E. coli and synthesized by IDT 
(Iowa, USA).  The codon-optimized gene and amino acid sequences of MbNHase are 
shown below.  
  
1  ATG CAT CTG TTC ACG TAT GAT CTG CAC CAT GAC GTG GGC GGT GCG   45 
1  Met  His     Leu   Phe  Thr   Tyr   Asp   Leu   His   His    Asp    Val    Gly  Gly   Ala     15 
 
46  GAA AAC ATG CTT CGT CTG CCG CTG GAT CGT CAC GAA CGT GAT TAC   90 
16  Glu   Asn   Met    Leu  Arg   Leu  Pro    Leu  Asp    Arg  His    Glu   Arg   Asp    Tyr    30 
 
91  CTG CCG TGG GAA CGT CAT ATT CAC GCT TTG GTA GTG TTG CTG GTC  135 
31  Leu   Pro    Trp   Glu    Arg   His   Ile    His    Ala    Leu  Val    Val    Leu  Leu   Val     45 
 
136 AAA CAA GGC CGT ATG AGC GTT GAT GAG TTG CGT CGC GGG GTC GAA   180 
46   Lys    Gln   Gly   Arg   Met   Ser     Val  Asp   Glu    Leu  Arg   Arg   Gly    Val   Glu       60 
 
181  GGC CTG CCT TCC TCA TTA GCG GAA CAG GCG AGC TAT TAC GAA AAG   225 
61   Gly  Leu  Pro  Ser  Ser  Leu  Ala  Glu  Gln  Ala  Ser  Tyr  Tyr  Glu  Lys       75 
 
226  TGG GGG TTG TCG GTG TCA CGT ATT CTG ACG GAA AAA GGC ACG GTC   270 
76    Trp   Gly    Leu   Ser   Val    Ser    Arg   Ile    Leu  Thr     Glu   Lys    Gly  Thr     Val       90 
 
271  TCA GGT CAC GAA CTG GAG CAA GGG TTC TTA GGT GTT CCG ACG ACG   315 
91     Ser   Gly    His   Glu    Leu  Glu    Gln   Gly    Phe   Leu  Gly   Val   Pro    Thr   Thr     105 
 
316  GAT CTG CCG CAG GTG CCC CGC TTC CAG GTG GGC CAA CGT GTA ATG   360 
106  Asp   Leu   Pro   Gln    Val    Pro  Arg    Phe  Gln    Val   Gly    Gln   Arg   Val   Met     120 
 
361  GTG CGT CCG TTC GGG ACA ACG TTT GCA TAC CGC CAA CCC CAT CTG   405 
121  Val   Arg    Pro    Phe  Gly    Thr   Thr    Phe  Ala    Tyr  Arg    Gln    Pro   His   Leu     135 
 
406  CGT GTT CCG GGG TAT GTT CAT GGA GCC GTG GGC ACT ATC GTG GAA   450 
136  Arg  Val  Pro  Gly  Tyr  Val  His  Gly  Ala  Val  Gly  Thr  Ile  Val  Glu      150 
 
451  CTG CCT GGG CTG TTT CAG GAT CCT ATG ACC GGC GCT TAC GGG GAA   495 
151  Leu   Pro   Gly    Leu   Phe  Gln   Asp   Pro    Met  Thr    Gly   Ala   Tyr    Gly    Glu    165 
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496  CGC GGT ACA GCT CAA CCG CTG TAC CGC GTG GCA TTC AGT CAT CGC   540 
166  Arg    Gly  Thr    Ala   Gln    Pro    Leu  Tyr  Arg     Val   Ala    Phe  Ser    His    Arg     180 
 
541  GCG CTG TGG CCG GAA GGG GCC GCG CAC GCC GAA CCT GGC GAA CTG  585 
181  Ala    Leu   Trp   Pro   Glu     Gly   Ala   Ala     His    Ala  Glu    Pro   Gly    Glu    Leu   195 
 
586  GAA GAT GGC GTA GTC GTG GAT GTC AGT CAG CCA TGG TTA GAG GCT  630 
196  Glu    Asp  Gly    Val    Val  Val    Asp   Val   Ser    Gln    Pro   Trp    Leu  Glu    Ala    210 
 
631  TTA TCT GAA GCT GAT TAC GCA CAG CGT CTG GCG ACG CTG CAT CGT   675 
211  Leu   Ser   Glu   Ala   Asp   Tyr    Ala   Gln    Arg  Leu   Ala     Thr   Leu  His     Arg    225 
 
676  GTG GCG TTT ACT CCT GAT AGC AAC CCG CCA CAA GCG CAT AAG CAC   720 
226  Val   Ala     Phe  Thr  Pro    Asp   Ser    Asn  Pro    Pro     Gln   Ala    His  Lys    His      240 
 
721  CAT CAT CAC CGT CAT CAT CAT GAC CAC CAT CAT CAT CAT CAT CAT     765 
241  His    His  His    Arg   His    His   His    Asp   His    His   His   His    His   His    His       255 
 
766  CAC CAC GCT ATG CAC GCC GAA CAT GAA GCT CAT ACC CAC GAT ACC   810 
256  His    His   Ala   Met    His    Ala   Glu   His    Glu   Ala    His   Thr    His   Asp   Thr     270 
 
811  CGT TAC GGC ACC GAA CAG GCC GCG GTA GCG AAG GAA GCG GCA TTG 855 
271  Arg    Tyr  Gly   Thr    Glu    Gln    Ala  Ala     Val   Ala    Lys   Glu    Ala   Ala     Leu  285 
 
856  GAT TTC CCG TAT CAG CCC TGG TGT GAA GCT CTG GTC CAG ACT CTT    900 
286  Asp    Phe  Pro   Tyr   Gln   Pro    Trp    Cys  Glu    Ala    Leu   Val  Gln    Thr   Leu     300 
 
901  ACC CGC CGC GGG GTC GTG CGC TCG GAC GAG CTG CAT GCT ACG CTG   945 
301  Thr    Arg  Arg   Gly    Val    Val   Arg   Ser   Asp    Glu    Leu  His    Ala  Thr     Leu    315 
 
946  GCA TCT CTG GAT GCA CTG CAA AAC TCA GGC GCA GGG CCT CAG CTG  990 
316  Ala  Ser  Leu  Asp  Ala  Leu  Gln  Asn  Ser  Gly  Ala  Gly   Pro   Gln  Leu  330 
 
991  GTG GCG CGC GCC TGG TCC GAT GCT GCT TTC GCG GAG TGG TTA CTG  1035 
331  Val   Ala   Arg   Ala     Trp    Ser  Asp    Ala  Ala     Phe  Ala   Glu    Trp    Leu  Leu     345 
 
1036 ACC GAT GCC GCT GCG GCG GCA GAG AGC TTA GCA ATC CGC ACC ACG 1080 
346  Thr    Asp   Ala   Ala    Ala   Ala    Ala    Glu   Ser     Leu  Ala    Ile     Arg   Thr    Thr    360 
 
1081 AAT TAC GAC GCG GAT CCG GCC TCT GCC GAG CGT GTG GGC GGC CAT 1125 
361  Asn  Tyr  Asp  Ala  Asp  Pro  Ala  Ser  Ala  Glu  Arg  Val  Gly   Gly  His   375 
 
1126  CGC CTG TTT TCG CAC AAT CAT ACG GAA TTA CGT GTC GTT GCG AAC 1170 
376   Arg  Leu  Phe  Ser  His  Asn  His  Thr  Glu  Leu  Arg  Val  Val  Ala  Asn   390 
 
1171  ACC GAC ACC GTA CAT AAC TTA GTA TGC TGC ACG CTG TGT TCT TGT 1215 
391   Thr    Asp    Thr   Val   His   Asn    Leu  Val    Cys   Cys  Thr     Leu  Cys  Ser    Cys    405 
 
1216  TAC CCG ACC GCG ATC TTA GGG CTT AGT CCA CCG TGG TAT AAG TCA 1260 
406    Tyr   Pro   Thr    Ala    Ile     Leu  Gly     Leu  Ser    Pro   Pro    Trp   Tyr   Lys    Ser    420 
 
1261  AAA GTG TTC CGC GCG CGT GCG GTC CGC GAA CCG CGT CGC TTG CTG 1305 
421    Lys   Val    Phe  Arg    Ala    Arg  Ala    Val   Arg   Glu    Pro   Arg    Arg   Leu  Leu     435 
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1306  CGT GAA GAA TTT GGC CTG GTG TTA CCG GAA GCG CGT GGT ATT CGT 1350 
436   Arg    Glu    Glu    Phe  Gly    Leu   Val   Leu  Pro   Glu    Ala    Arg   Gly   Ile    Arg     450 
 
1351  GTT CAT GAT AGC ACT GCA GAT CTG CGT TAC ATG GTT CTG CCC CAA 1395 
451    Val   His   Asp   Ser    Thr    Ala   Asp   Leu   Arg   Tyr   Met   Val   Leu   Pro   Gln     465 
 
1396 CGC CCG CAA GGC ACA GAA GGC TGG TCT GAG GAA CAT CTG CGT ACC 1440 
466   Arg    Pro    Gln   Gly   Thr   Glu    Gly     Trp    Ser  Glu    Glu    His   Leu   Arg    Thr   480 
 
1441 ATC GTT ACC CGC GAT AGC CTT CTC GGT ACC GCG GTG CCG CGC GTG  1485 
481  Ile      Val   Thr    Arg   Asp   Ser    Leu  Leu   Gly  Thr   Ala    Val    Pro   Arg  Val       495 
 
1486  GAT TAA   1491 
496   Asp  End     497 
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Figure SI-2.  Gel filtration elution profile of MbNHase for the determination of the 
quaternary structure in solution and molecular mass.  Marker proteins used for gel 
filtration: (i) cytochrome c, 12.4 kDa, (ii) carbonic anhydrase, 29 kDa, (iii) albumin 66 
kDa, (iv) alcohol dehydrogenase, 150 kDa, and (v) beta-amylase, 200 kDa.  Peaks at 
75.54 mL and 85.10 mL correspond to dimer and monomer of MbNHase, respectively.   
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Figure SI-3.     SDS-PAGE analysis of apo-MbNHase: lane 1 molecular weight 
standards, lane 2 purified apo MbNHase. 
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